745 related articles for article (PubMed ID: 26510912)
1. Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine.
Subbiah V; Wagner MJ; McGuire MF; Sarwari NM; Devarajan E; Lewis VO; Westin S; Kato S; Brown RE; Anderson P
Oncotarget; 2015 Dec; 6(38):40642-54. PubMed ID: 26510912
[TBL] [Abstract][Full Text] [Related]
2. Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy.
Zhao J; Dean DC; Hornicek FJ; Yu X; Duan Z
Cancer Lett; 2020 Apr; 474():158-167. PubMed ID: 31987920
[TBL] [Abstract][Full Text] [Related]
3. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
4. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
[TBL] [Abstract][Full Text] [Related]
6. Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.
Carlson JA; Caldeira Xavier JC; Tarasen A; Sheehan CE; Otto G; Miller VA; Stephens PJ; Elvin JA; Vergilio JA; Suh J; Gay LM; Ross JS
Am J Dermatopathol; 2017 Jan; 39(1):1-13. PubMed ID: 28045747
[TBL] [Abstract][Full Text] [Related]
7. Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma.
Xiao X; Wang W; Zhang H; Gao P; Fan B; Huang C; Fu J; Chen G; Shi L; Zhu H; Li X; Li J; Fan H; Wu Z; Guo Z; Hu Y; Wu S; Yu X; Xu C; Wang Z
Tumour Biol; 2015 Apr; 36(4):2427-35. PubMed ID: 25431261
[TBL] [Abstract][Full Text] [Related]
8. General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study.
Lee H; El Jabbour T; Ainechi S; Gay LM; Elvin JA; Vergilio JA; Suh J; Ramkissoon SH; Ali SM; Schrock A; Fabrizio D; Frampton G; Nazeer T; Miller VA; Stephens PJ; Ross JS
Hum Pathol; 2017 Dec; 70():84-91. PubMed ID: 29079173
[TBL] [Abstract][Full Text] [Related]
9. Genomic landscape of salivary gland tumors.
Kato S; Elkin SK; Schwaederle M; Tomson BN; Helsten T; Carter JL; Kurzrock R
Oncotarget; 2015 Sep; 6(28):25631-45. PubMed ID: 26247885
[TBL] [Abstract][Full Text] [Related]
10. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.
Kim HS; Lee H; Shin SJ; Beom SH; Jung M; Bae S; Lee EY; Park KH; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Noh SH; Rha SY; Kim H; Paik S
Oncotarget; 2017 Jun; 8(24):38389-38398. PubMed ID: 28418920
[TBL] [Abstract][Full Text] [Related]
11. Molecular Profiling of Clear Cell Ovarian Cancers: Identifying Potential Treatment Targets for Clinical Trials.
Friedlander ML; Russell K; Millis S; Gatalica Z; Bender R; Voss A
Int J Gynecol Cancer; 2016 May; 26(4):648-54. PubMed ID: 26937756
[TBL] [Abstract][Full Text] [Related]
12. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional Profiling Identifies the Signaling Axes of IGF and Transforming Growth Factor-b as Involved in the Pathogenesis of Osteosarcoma.
Yang R; Piperdi S; Zhang Y; Zhu Z; Neophytou N; Hoang BH; Mason G; Geller D; Dorfman H; Meyers PA; Healey JH; Phinney DG; Gorlick R
Clin Orthop Relat Res; 2016 Jan; 474(1):178-89. PubMed ID: 26463566
[TBL] [Abstract][Full Text] [Related]
14. RUNX2 (6p21.1) amplification in osteosarcoma.
Gupta S; Ito T; Alex D; Vanderbilt CM; Chang JC; Islamdoust N; Zhang Y; Nafa K; Healey J; Ladanyi M; Hameed MR
Hum Pathol; 2019 Dec; 94():23-28. PubMed ID: 31669178
[TBL] [Abstract][Full Text] [Related]
15. Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation.
Armstrong AE; Walterhouse DO; Leavey PJ; Reichek J; Walz AL
Pediatr Blood Cancer; 2019 Jan; 66(1):e27493. PubMed ID: 30318721
[TBL] [Abstract][Full Text] [Related]
16. Molecular characterization of the response to chemotherapy in conventional osteosarcomas: predictive value of HSD17B10 and IFITM2.
Salas S; Jézéquel P; Campion L; Deville JL; Chibon F; Bartoli C; Gentet JC; Charbonnel C; Gouraud W; Voutsinos-Porche B; Brouchet A; Duffaud F; Figarella-Branger D; Bouvier C
Int J Cancer; 2009 Aug; 125(4):851-60. PubMed ID: 19449377
[TBL] [Abstract][Full Text] [Related]
17. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
19. [Mutation characteristics of osteosarcoma: a single center study of 64 cases using next-generation sequencing].
Gao DL; Dong RF; Liu WF; Gong LH; Xu HR; Niu XH; Ding Y
Zhonghua Bing Li Xue Za Zhi; 2023 Apr; 52(4):370-375. PubMed ID: 36973198
[No Abstract] [Full Text] [Related]
20. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies.
Ross JS; Ali SM; Wang K; Palmer G; Yelensky R; Lipson D; Miller VA; Zajchowski D; Shawver LK; Stephens PJ
Gynecol Oncol; 2013 Sep; 130(3):554-9. PubMed ID: 23791828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
